Stock 4577 DAITO PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Daito Pharmaceutical Co.,Ltd.

Equities

4577

JP3486150000

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-07-10 am EDT 		5-day change 1st Jan Change
2,306 JPY -0.17% Intraday chart for Daito Pharmaceutical Co.,Ltd. +1.77% +21.05%
May. 14 Tranche Update on Daito Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on April 12, 2024. CI
May. 13 Daito Pharmaceutical Co.,Ltd.'s Equity Buyback announced on April 12, 2024, has closed with 350,000 shares, representing 2.23% for ¥868.86 million. CI

Valuation

Fiscal Period: Maggio 2018 2019 2020 2021 2022 2023
Capitalization 1 45,238 42,109 56,950 44,980 37,154 33,086
Enterprise Value (EV) 1 50,962 45,296 57,026 45,000 36,220 34,437
P/E ratio 14.9 x 12 x 14.2 x 10.5 x 7.8 x 9.21 x
Yield 0.91% 1.13% 0.92% 1.4% 1.91% 2.61%
Capitalization / Revenue 1.13 x 1.02 x 1.27 x 0.92 x 0.85 x 0.73 x
EV / Revenue 1.28 x 1.1 x 1.27 x 0.92 x 0.83 x 0.76 x
EV / EBITDA 7.26 x 6.12 x 6.86 x 4.96 x 3.67 x 3.79 x
EV / FCF 35.7 x 20.1 x 27.7 x -16.2 x -89.1 x -37.5 x
FCF Yield 2.8% 4.98% 3.61% -6.18% -1.12% -2.67%
Price to Book 1.61 x 1.36 x 1.57 x 1.08 x 0.79 x 0.65 x
Nbr of stocks (in thousands) 13,765 13,765 14,368 15,085 15,617 15,803
Reference price 2 3,286 3,059 3,964 2,982 2,379 2,094
Announcement Date 8/30/18 8/30/19 8/28/20 8/26/21 8/25/22 8/30/23
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: May 2018 2019 2020 2021 2022 2023
Net sales 1 39,875 41,134 44,991 48,714 43,464 45,101
EBITDA 1 7,021 7,399 8,312 9,070 9,881 9,082
EBIT 1 4,168 4,547 5,362 5,916 6,568 5,212
Operating Margin 10.45% 11.05% 11.92% 12.14% 15.11% 11.56%
Earnings before Tax (EBT) 1 4,262 4,619 5,595 5,873 6,720 5,077
Net income 1 3,041 3,513 3,944 4,246 4,668 3,600
Net margin 7.63% 8.54% 8.77% 8.72% 10.74% 7.98%
EPS 2 220.9 255.2 279.5 282.7 304.9 227.4
Free Cash Flow 1 1,426 2,256 2,059 -2,780 -406.6 -918
FCF margin 3.58% 5.49% 4.58% -5.71% -0.94% -2.04%
FCF Conversion (EBITDA) 20.31% 30.5% 24.77% - - -
FCF Conversion (Net income) 46.89% 64.23% 52.2% - - -
Dividend per Share 2 30.00 34.55 36.36 41.82 45.45 54.55
Announcement Date 8/30/18 8/30/19 8/28/20 8/26/21 8/25/22 8/30/23
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: Maggio 2020 S1 2021 S1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3
Net sales 1 23,253 26,035 10,717 22,463 11,120 9,881 12,041 11,326 23,367 11,203 10,531 12,178 11,932 24,110 10,552
EBITDA - - - - - - - - - - - - - - -
EBIT 1 2,829 3,512 1,517 3,877 1,769 907 1,501 1,325 2,826 1,280 1,101 1,080 1,209 2,289 816
Operating Margin 12.17% 13.49% 14.16% 17.26% 15.91% 9.18% 12.47% 11.7% 12.09% 11.43% 10.45% 8.87% 10.13% 9.49% 7.73%
Earnings before Tax (EBT) 1 2,963 3,549 1,454 4,096 1,813 811 1,470 1,235 2,705 1,291 1,080 1,092 1,223 2,315 1,125
Net income 1 2,002 2,423 952 2,777 1,201 690 946 816 1,762 898 940 683 869 1,552 787
Net margin 8.61% 9.31% 8.88% 12.36% 10.8% 6.98% 7.86% 7.2% 7.54% 8.02% 8.93% 5.61% 7.28% 6.44% 7.46%
EPS 2 145.0 162.1 - 183.7 77.96 - 59.74 - 111.3 56.84 - 43.27 - 98.22 50.13
Dividend per Share 18.18 20.91 - 22.73 - - - - 27.27 - - - - 30.00 -
Announcement Date 1/14/20 1/14/21 1/14/22 1/14/22 4/14/22 7/14/22 10/13/22 1/13/23 1/13/23 4/13/23 7/14/23 10/12/23 1/12/24 1/12/24 4/12/24
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: Maggio 2018 2019 2020 2021 2022 2023
Net Debt 1 5,724 3,187 76 20 - 1,351
Net Cash position 1 - - - - 934 -
Leverage (Debt/EBITDA) 0.8153 x 0.4307 x 0.009143 x 0.002205 x - 0.1488 x
Free Cash Flow 1 1,426 2,256 2,059 -2,781 -407 -918
ROE (net income / shareholders' equity) 11.1% 11.7% 11.5% 10.6% 10.3% 7.15%
ROA (Net income/ Total Assets) 5.61% 6.05% 6.64% 6.6% 6.69% 4.81%
Assets 1 54,227 58,066 59,432 64,301 69,752 74,869
Book Value Per Share 2 2,038 2,248 2,520 2,759 3,010 3,206
Cash Flow per Share 2 124.0 132.0 213.0 224.0 279.0 228.0
Capex 1 3,821 3,630 2,731 6,318 4,627 5,505
Capex / Sales 9.58% 8.82% 6.07% 12.97% 10.65% 12.21%
Announcement Date 8/30/18 8/30/19 8/28/20 8/26/21 8/25/22 8/30/23
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
DAITO PHARMACEUTICAL CO.,LTD. Stock Daito Pharmaceutical Co.,Ltd.
+21.05% 219M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+26.40% 45.55B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+33.33% 23.65B
SANDOZ GROUP AG Stock Sandoz Group AG
+25.02% 16.22B
CIPLA LIMITED Stock Cipla Limited
+21.00% 14.62B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+69.09% 14.04B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-13.71% 6.36B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+15.70% 5.77B
GEDEON RICHTER Stock Gedeon Richter
+12.06% 4.8B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4577 Stock
  4. Financials Daito Pharmaceutical Co.,Ltd.